Urogen Pharma (NASDAQ:URGN) Given New $75.00 Price Target at HC Wainwright

Urogen Pharma (NASDAQ:URGN) had its price objective raised by investment analysts at HC Wainwright from $45.00 to $75.00 in a report issued on Thursday, Marketbeat.com reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 61.53% from the company’s current price.

A number of other research firms also recently issued reports on URGN. TD Cowen boosted their price objective on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. Oppenheimer raised their price objective on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $44.00 price target on shares of Urogen Pharma in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

Urogen Pharma Price Performance

Shares of NASDAQ URGN opened at $46.43 on Thursday. The stock’s fifty day moving average price is $35.73 and its two-hundred day moving average price is $26.80. Urogen Pharma has a one year low of $15.86 and a one year high of $47.84. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -16.88 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to the consensus estimate of $63.55 million. On average, equities analysts anticipate that Urogen Pharma will post -0.76 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the transaction, the insider directly owned 119,763 shares in the company, valued at $4,790,520. This represents a 7.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 25,222 shares of company stock worth $892,661. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of URGN. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after purchasing an additional 486 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares during the last quarter. Osaic Holdings Inc. increased its stake in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after buying an additional 5,571 shares during the period. Finally, ProShare Advisors LLC bought a new position in Urogen Pharma in the 4th quarter valued at approximately $206,000. Institutional investors own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.